__NUXT_JSONP__("/drugs/Lifileucel", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:b,chebiId:b,chemicalFormula:b,definition:"A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro.",fdaUniiCode:"R0835E18NH",identifier:"C120552",preferredName:a,semanticType:"Cell",subclassOf:["C28699"],synonyms:["Autologous TIL LN-144","Autologous Tumor Infiltrating Lymphocytes LN-144","Contego","LIFILEUCEL","LN-144",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLifileucel",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Lifileucel","","2021-10-30T13:20:04.303Z")));